Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at teste forskellige doser af BI 1584862 hos mennesker med en særskilt form for aldersrelateret makuladegeneration (AMD) kaldet geografisk atrofi

29. september 2026 opdateret af: Boehringer Ingelheim

JADE: Fase II-forsøg i patienter med geografisk atrofi: En randomiseret, dobbeltmasket, placebokontrolleret, dosisfindende undersøgelse til evaluering af effektiviteten og sikkerheden af ​​BI 1584862

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.

This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.

Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

150

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arizona
      • Gilbert, Arizona, Forenede Stater, 85297
        • Associated Retina Consultants
      • Phoenix, Arizona, Forenede Stater, 85020
        • Associated Retina Consultants, Ltd.
      • Phoenix, Arizona, Forenede Stater, 85050
        • Cameron Ria, LLC
      • Scottsdale, Arizona, Forenede Stater, 85255
        • Retina Macula Institute of Arizona
    • California
      • Beverly Hills, California, Forenede Stater, 90211
        • Retina-Vitreous Associates Medical Group
      • Glendale, California, Forenede Stater, 91204
        • Global Research Management
      • Huntington Beach, California, Forenede Stater, 92647
        • Retina Associates of Southern California
      • Modesto, California, Forenede Stater, 95356
        • Retinal Consultants Medical Group, Inc
      • Mountain View, California, Forenede Stater, 94040
        • Northern California Retina Vitreous Associates MedicalGroup, Inc.
      • Newport Beach, California, Forenede Stater, 92663
        • Eye Research Foundation
      • Poway, California, Forenede Stater, 92064
        • Retina Consultants of San Diego
      • Sacramento, California, Forenede Stater, 95825
        • Retinal Consultants Medical Group
      • Walnut Creek, California, Forenede Stater, 94598
        • Bay Area Retina Associates - Walnut Creek
    • Colorado
      • Denver, Colorado, Forenede Stater, 80222
        • Retina Specialists of Colorado Research, LLC
    • Connecticut
      • Greenwich, Connecticut, Forenede Stater, 06830
        • Coastal Eye Surgeons
    • Florida
      • Gainesville, Florida, Forenede Stater, 32605
        • Vitreo Retinal Associates - Gainesville
      • Miami, Florida, Forenede Stater, 33143
        • MedEye Associates
      • Pinellas Park, Florida, Forenede Stater, 33782
        • Eye Associates of Pinellas
      • Stuart, Florida, Forenede Stater, 34994
        • East Florida Eye Institute
      • Winter Haven, Florida, Forenede Stater, 33880
        • Center for Retina and Macular Disease
    • Georgia
      • Augusta, Georgia, Forenede Stater, 30909
        • Southeast Retina Center, PC
    • Illinois
      • Oak Park, Illinois, Forenede Stater, 60304
        • Illinois Retina Associates - Oak Park
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40206
        • The Eye Care Institute
    • Maryland
      • Hagerstown, Maryland, Forenede Stater, 21740
        • Cumberland Valley Retina Consultants
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Ophthalmic Consultants of Boston
    • Missouri
      • Columbia, Missouri, Forenede Stater, 65212
        • University of Missouri Health System
    • New Jersey
      • Teaneck, New Jersey, Forenede Stater, 07666
        • NJRetina
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97401
        • Verum Research, LLC
      • Portland, Oregon, Forenede Stater, 97221
        • Retina Northwest
      • Portland, Oregon, Forenede Stater, 97225
        • EyeHealth Northwest
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Mid Atlantic Retina - Wills Eye Hospital
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29414
        • Charleston Neuroscience Institute - Charleston
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Tennessee Retina
    • Texas
      • Austin, Texas, Forenede Stater, 78750
        • Austin Clinical Research, LLC
      • Beaumont, Texas, Forenede Stater, 77707
        • Retina Consultants of Texas - Beaumont
      • Dallas, Texas, Forenede Stater, 75231
        • Retina Foundation of the Southwest
      • Plano, Texas, Forenede Stater, 75024
        • Red River Research Partners, LLC - Plano
      • San Antonio, Texas, Forenede Stater, 78240
        • Retinal Consultants of San Antonio
      • Schertz, Texas, Forenede Stater, 78154
        • Retina Consultants of Texas - Schertz
      • The Woodlands, Texas, Forenede Stater, 77384
        • Retina Consultants of Texas-The Woodlands-67575
    • Virginia
      • Falls Church, Virginia, Forenede Stater, 22042
        • Emerson Clinical Research Institute
      • Lynchburg, Virginia, Forenede Stater, 24502
        • Piedmont Eye Center
    • Washington
      • Bellevue, Washington, Forenede Stater, 98004
        • Pacific Northwest Retina
      • Arecibo, Puerto Rico, 00612
        • Emanuelli Research & Development Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria:

  • Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:

    • If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
    • At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
    • The foveal center point must not be involved in any atrophic lesion
    • Lesion(s) must reside completely within the FAF image
  • Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).

  • Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.

  • Age ≥50 years.

  • Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.

  • Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation

Exclusion criteria:

  • Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.

  • Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.

  • Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.

  • Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:

    • uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
    • clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
    • history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
    • anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
    • other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
  • Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:

    • put the participant at risk because of participation in the study
    • influence the results of the study
    • cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
  • Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.

  • Active intraocular inflammation in the study eye.

  • Active infectious conjunctivitis in either eye. Further exclusion criteria apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo-matchende BI 1584862

Placebo-matching BI 1584862

Eksperimentel: BI 1584862 dosis 1

BI 1584862

Eksperimentel: BI 1584862 dosis 2

BI 1584862

Eksperimentel: BI 1584862 dosis 3

BI 1584862

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Tidsramme: Up to week 50.

mm is millimeters.

Up to week 50.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Forekomst af TEAES fra lægemiddeladministration indtil uge 52
Tidsramme: Op til uge 52.
Op til uge 52.
Ændring fra baseline i partiel dæmpning som en procentdel af ellipsoidzonen (EZ) ved makulærområdet med tykkelse <20 mikrogram (μm) op til uge 50 vurderet ved volumetrisk optisk kohærenstomografi (OCT) i undersøgelsesøjet
Tidsramme: Op til uge 50.
Op til uge 50.
Ændring fra baseline i kvadratrodstransformeret geografisk atrofi (GA) område som målt ved fundus autofluorescens (FAF) ved uge 50 (udtrykt i mm) i undersøgelsesøjet
Tidsramme: Ved baseline og i uge 50.
Ved baseline og i uge 50.
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Tidsramme: Up to week 50.

EZ stands for ellipsoid zone. OCT stands for optical coherence tomography.

Up to week 50.
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Tidsramme: Up to week 50.

GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters.

Up to week 50.
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Tidsramme: Up to week 50.

ETDRS is early treatment diabetic retinopathy study.

Up to week 50.
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Tidsramme: At baseline and at week 50.

ETDRS is early treatment diabetic retinopathy study.

At baseline and at week 50.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. januar 2025

Primær færdiggørelse (Anslået)

22. december 2026

Studieafslutning (Anslået)

5. januar 2027

Datoer for studieregistrering

Først indsendt

7. januar 2025

Først indsendt, der opfyldte QC-kriterier

7. januar 2025

Først opslået (Faktiske)

10. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 1484-0005
  • U1111-1309-9115 (Registry Identifier: WHO International Clinical Trials Registry Platform (ICTRP))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

IPD-delingstidsramme

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

IPD-delingsadgangskriterier

For study documents - upon signing of a 'Document Sharing Agreement'.

For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .